Big Data In The Big Easy: Sapien Versus Surgery Results Get Top ACC Billing
This article was originally published in The Gray Sheet
Transcatheter aortic heart valve data, and Edwards Lifesciences' Sapien valve in particular, are set to take the spotlight at yet another major cardiology conference this weekend.
You may also be interested in...
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.
Data from the first-ever randomized trial of a transcatheter aortic heart valve show a substantial one-year survival benefit for Edwards Lifesciences' Sapien versus standard medical therapy, giving the firm major momentum as it prepares to submit one of two upcoming PMAs for the device
One-year efficacy results reported May 25 at the EuroPCR meeting in Paris could help Medtronic claim a bigger stake in the drug-eluting stent market, where Abbott and Boston Scientific have increasingly dominated